Interviewer: Is that an important message to say start as soon as you deem it clinically

appropriate? Is that something that they should emphasize a little bit more or
should they leave it as it is now where it’s in the data a little bit?

Respondent: They should emphasize.

Interviewer: Where do you think that would be appropriate to emphasize? Would it be here in
the subgroup analysis? Would it be on a different page? Where do you think that
idea should be woven in?

Respondent: Right in the box [Unintelligible] for radiation. It can save hours and start the
patient who’s targeted in two weeks [Unintelligible]. That’s what it is showing
here.

Interviewer: So just add that sentence to this box and that’s good?

Respondent: Yes.

Interviewer: Great, there are several pages here that I think we’re just going to skip over,
safety and tolerability, dosage and administration, information about the Pacific
trial and then, here is information about the AJCC 7th and 8th so they do have a
page about that. Just real quick, is this important to you because you were talking
about that a moment ago? Do you think that they should emphasize this or is this
more of a resource if needed and questions come up?

Respondent: Resource if needed, they should emphasize this.

Interviewer: Okay.

Respondent: They should be ready to explain this information. [It’s a way off].

Interviewer: Well, then they do also –

Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

The only transcription company with ListenLinkTM!

Respondent: It’s very nice.

Interviewer: Which one is very nice, Doctor? This one?

Respondent: [Unintelligible]. These tables are very nice. It tells us exactly how they’re stating a
change.

Interviewer: You like the details and there’s a reference in case it’s needed. How about this?
This is not as detailed but it is talking about Stage 3 and it’s visually depicting
Stage 3. What do you think about that approach?

Respondent: It’s very good. That’s very good. It compliments. It’s good for the patients. It may
not be good for me but good for the patient.

Interviewer: You would want it, the charts, okay. Let’s go ahead and we can skip over this,
important safety information. That will always be in there and I do want to take a
few moments to speak about the back cover here, Doctor. This is the back cover
and I’m hoping that you can just tell me if this has to serve two distinct purposes.
It needs to be so if the rep has time to sit and chat with you and give you the full
detail. This needs to be a good summary of that and then, the second purpose that
it needs to serve is if the rep doesn’t have a lot of time and only has 20 seconds in
the hallway, this is the page that they would show you. How does it do in terms of
meeting those two distinct objectives?

Respondent: Very good, it’s a snapshot of all the information which we have discussed.

Interviewer: Is anything missing? Do you want them to add anything or could anything be deleted
and save a little bit of room under that cover? Any ideas there?

Respondent: No.

Interviewer: No, okay, and the other question I have about that cover is that they have both [KM
curse] for both OSN PFS and should they take away the Kaplan Meier curve for PFS
and just put a bullet there about PFS?

Respondent: No, meet the curve.

Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 2 of 10
Interviewer: Okay, why is that? Why do you recommend they meet the curve?

Respondent: Any start is does that show improvement in overall survival or overall survival
meaning less and less as the time goes so PFS is also an important factor especially
in Stage 3.

Interviewer: Okay, we need both, got it. Doctor, those are all the pages that I wanted you to
review for me here and now that you’ve seen everything, I just want you to sum it
up for me here. What are they saying about Imfinzi? What’s the story that you’re
getting for this?

Respondent: They are saying that Stage 3 on the second one is dismal prognosis, not significant
improvement in survival rates for the last 10 years and Imfinzi is the only approved
immunotherapy which improves overall survival and PFS and Category 1 NCCS and
update analysis showed there’s significant improvement in three years
[Unintelligible] BFS and this should be standard of care for patients Stage 3 on the
second one.

Interviewer: Is what you saw here enough to make you think about using this protocol and
Pacific regimen in Stage 3, B and C patients?

Respondent: Absolutely.

Interviewer: What specific piece of information tipped the scales there? What did you see to
make you think “Yes, Stage 3 B and C is [curative intent]?”

Respondent: I’m sorry?

Interviewer: What did you see here that shifted your thinking to make you think of using this in
those patients?

Respondent: We don’t have much options. [Unintelligible] motivation is curative intent but still
the [Unintelligible] is this one so adding more [Unintelligible].

Interviewer: Just overall, what can they change to make it as good as they can possibly be?
What should be tweaked here?

Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 3 of 10
Respondent: I think it’s wonderful already and good to excellent piece as an illustration.

Interviewer: Let’s talk about your interaction with the patients now that you’ve seen this. How,
if at all, may you talk to your patients differently about CRT followed by Imfinzi?

Respondent: There’s improvement in overall survival which is obtained so this came the
treatment paradigm in these patients.

Interviewer: Do you tell your patients? Do you tell them there’s a change in overall survival or
do you show them a graph? How detailed do you get with your patients about this?

Respondent: By graph and if we have information in the graph that the patient did not
understand, we, in general, say there’s an overall survival.

Interviewer: When do you talk to your patients, do you tell them about the two phases of their
treatment paths? Do you say, first, it’s CRT and then, we go into immunotherapy
after that’s done or do you wait until CRT is done before you tell them about
immunotherapy?

Respondent: Yes, I can. I tell them that’s the [Unintelligible] thing and when you can plan. You
really [Unintelligible] when the time comes, we will go over the side effects of
immunotherapy. You really have to prepare them from the beginning.

Interviewer: Okay, you prepare them from the beginning. How do you describe it to them,
Doctor? How do you help prepare them mentally after CRT is done and now, you
have another year of treatment ahead of you? What do you say to help them accept
that?

Respondent: I really tell them AP is a very [Unintelligible] terrible cancer so anything we can do
more to improve overall survival. Cancer not come back actually. Cancer not
coming back, anything which is available will be helpful and patients understand
[Unintelligible] disease, the chance of cure is very small so they are ready to get
treatment if it has shown the whole world benefit.

Interviewer: Okay, do you say that there has been a treatment that has been shown to improve
benefit and it’s called Imfinzi? Do you actually get that specific?

Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 4 of 10
Respondent: Yes, if you don’t have the time goals then, I give in too much for the Imfinzi. I may
not see them on the first visit but when they [Unintelligible] the side effects of
Imfinzi, then we go from there.

Interviewer: Before I even pull up the last thing I’m going to ask you to do, I am wondering too.
I know that there is a certain subset of patients that may be hesitant to go on
immunotherapy after CRT or maybe refusing. Does this information give you more
confidence to push those patients to encourage them further?

Respondent: Absolutely.

Interviewer: In those patients that are on the fence or are refusing, what would you say about
the data to help convince them? What would you tell them?

Respondent: Improvement in overall survival.

Interviewer: Can’t get much more clear than that, right?

Respondent: Can’t get more clear than that.

Interviewer: [Laughter] Great, let me just pull up that sheet again. You rated it straight sevens
when we first sat down to chat and now, that you’ve reviewed it and we’ve gone
through it in a lot of detail, is it still all sevens or do you want to bump anything
down?

Respondent: All sevens.

Interviewer: Still all sevens, okay. Let me just take a quick moment here. Bear with me. I’m
going to check and see if there are any final questions. [Pause] Bear with me for
just one second, Doctor. [Pause] In general, does this data increase your belief in
curative intent with Stage 3? Do they achieve that goal?

Respondent: Yes.

Interviewer: Even B and C or is it still just for A?

Respondent: B and C also.

Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 5 of 10
Interviewer: B and C also. Great, just bear with me one more quick second here. [Pause] Okay, I
think I’ve asked you everything I needed to ask you here, Doctor. Thank you so
much for jumping on and doing this and going through and giving me your
feedback. I appreciate it.

Respondent: Thank you so much. You take care.

Interviewer: Have a good one, bye bye.

Respondent: Thank you. [Pause]

- End of Recording -

Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 6 of 10
Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 7 of 10
Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 8 of 10
Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 9 of 10
Transcripts@civi.com | www.TranscriptionWing.com | 888-223-9488

Page 10 of 10